Cambridge Oncometrix’s pivotal clinical study to validate a new test for the early detection of prostate cancer has started to recruit patients.
The study is led by UCL and is conducted in three hospitals: in London (UCLH), Leeds (NHS Teaching Hospital), and Norwich (NNUHFT).

The Head of the Study termed ‘PLiS’ is Prof. Mark Emberton, Dean of the UCL Faculty of Medical Sciences. The results of the test performance evaluation will be used to seek regulatory approvals of the Oncometrix diagnostic products in the UK/EU and to enter international markets.


Learn more: